Accepted for/Published in: Journal of Medical Internet Research
Date Submitted: Nov 27, 2020
Date Accepted: May 30, 2021
Date Submitted to PubMed: Sep 14, 2021
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Process evaluations of a web-based intervention to increase handwashing during a pandemic: Moving Germ Defence from a randomised controlled trial to public dissemination
ABSTRACT
Background:
Washing hands helps prevent transmission of seasonal and pandemic respiratory viruses. The PRIMIT study developed a fully automated, digital intervention to promote handwashing. In a randomised controlled trial during the Swine Flu outbreak, participants who had access to the intervention reported washing their hands more and experienced less respiratory tract infections than those without access. Using these findings, the intervention was subsequently adapted, renamed ‘Germ Defence’, and a study designed to assess a preliminary dissemination of the intervention to the general public to help prevent the spread of seasonal colds and flu.
Objective:
This paper compares process evaluations of the PRIMIT trial and Germ Defence dissemination to examine: 1) how online research enrollment procedures impacted on who used the intervention; 2) intervention usage in the two contexts; 3) whether increased intentions to wash hands are replicated once disseminated. The purpose of this paper is to provide insight so that the Germ Defence intervention could be optimized for wide-scale dissemination in the event of a global pandemic.
Methods:
The PRIMIT trial ran between 2010 and 2012 recruiting participants offline from General Practices, with restricted access to the intervention (N=9155). Germ Defence was disseminated as an open access website for use by the general public from 2016 to 2019 (N=624). The process evaluation plan was developed using Medical Research Council guidance and the framework for Analysing and Measuring Usage and Engagement Data. Both interventions contained a goal-setting section where users self-reported current and intended handwashing behaviour across seven situations.
Results:
During online enrolment, 54.30% (n=17,511) of PRIMIT study participants dropped out of the study compared to 36.46% (n=358) of Germ Defence users. Having reached the intervention, 93.79% (n=8586) of PRIMIT users completed the core section, whereas 65.06% (n=406) of Germ Defence users reached the same point. Users across both studies selected to increase their handwashing in five out of seven situations, including before eating snacks (PRIMIT MD=1.040 [CI 1.016, 1.063], Germ Defence MD=.949 [CI 766, 1.132]) and after blowing their nose, sneezing or coughing (PRIMIT MD=.995 [CI .972, 1.019], Germ Defence MD=.842 [CI .675, 1.008]).
Conclusions:
By comparing a preliminary dissemination of Germ Defence to the PRIMIT trial we have been able to examine the potential effects of research procedures on uptake and attrition, such as the sizeable dropout during the PRIMIT trial enrolment procedure that may have led to a more motivated sample. The Germ Defence study highlighted points of attrition within the intervention. Despite sample bias in the trial context, the intervention replicated increases in intentions to handwash when used ‘in the wild’. This preliminary dissemination study informed the adaptation of the intervention for the COVID-19 health emergency, and it has now been disseminated globally. Clinical Trial: ISRCTN75058295
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.